Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 2
2006 1
2007 2
2008 1
2009 2
2010 2
2011 1
2012 2
2013 1
2014 1
2016 2
2018 1
2019 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat.
Mediouni S, Chinthalapudi K, Ekka MK, Usui I, Jablonski JA, Clementz MA, Mousseau G, Nowak J, Macherla VR, Beverage JN, Esquenazi E, Baran P, de Vera IMS, Kojetin D, Loret EP, Nettles K, Maiti S, Izard T, Valente ST. Mediouni S, et al. Among authors: loret ep. mBio. 2019 Feb 5;10(1):e02662-18. doi: 10.1128/mBio.02662-18. mBio. 2019. PMID: 30723126 Free PMC article.
Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
Loret EP, Darque A, Jouve E, Loret EA, Nicolino-Brunet C, Morange S, Castanier E, Casanova J, Caloustian C, Bornet C, Coussirou J, Boussetta J, Couallier V, Blin O, Dussol B, Ravaux I. Loret EP, et al. Retrovirology. 2016 May 9;13(1):35. doi: 10.1186/s12977-016-0264-y. Retrovirology. 2016. PMID: 27160192 Free PMC article. No abstract available.
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
Loret EP, Darque A, Jouve E, Loret EA, Nicolino-Brunet C, Morange S, Castanier E, Casanova J, Caloustian C, Bornet C, Coussirou J, Boussetta J, Couallier V, Blin O, Dussol B, Ravaux I. Loret EP, et al. Retrovirology. 2016 Apr 1;13:21. doi: 10.1186/s12977-016-0251-3. Retrovirology. 2016. PMID: 27036656 Free PMC article. Clinical Trial.
Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.
Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal DN, Loret EP, Rasmussen RA, Ruprecht RM. Lakhashe SK, et al. Among authors: loret ep. Vaccine. 2014 Nov 12;32(48):6527-36. doi: 10.1016/j.vaccine.2014.08.065. Epub 2014 Sep 20. Vaccine. 2014. PMID: 25245933 Free PMC article.
Identification of a highly conserved surface on Tat variants.
Mediouni S, Darque A, Ravaux I, Baillat G, Devaux C, Loret EP. Mediouni S, et al. Among authors: loret ep. J Biol Chem. 2013 Jun 28;288(26):19072-80. doi: 10.1074/jbc.M113.466011. Epub 2013 May 15. J Biol Chem. 2013. PMID: 23678001 Free PMC article.
Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein.
Mediouni S, Darque A, Baillat G, Ravaux I, Dhiver C, Tissot-Dupont H, Mokhtari M, Moreau H, Tamalet C, Brunet C, Paul P, Dignat-George F, Stein A, Brouqui P, Spector SA, Campbell GR, Loret EP. Mediouni S, et al. Among authors: loret ep. Infect Disord Drug Targets. 2012 Feb;12(1):81-6. doi: 10.2174/187152612798994939. Infect Disord Drug Targets. 2012. PMID: 22280310
21 results